PMID- 12186818
OWN - NLM
STAT- MEDLINE
DCOM- 20020906
LR  - 20191210
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 166
IP  - 4
DP  - 2002 Aug 15
TI  - Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has 
      greater test efficiency than specific antibodies for identification of 
      diisocyanate asthma.
PG  - 445-50
AB  - We previously reported that diisocyanate-human serum albumin (DIISO-HSA) 
      stimulated production of monocyte chemoattractant protein-1 (MCP-1) by peripheral 
      blood mononuclear cells is significantly associated with a clinical diagnosis of 
      diisocyanate asthma (DA). Others have reported that antibodies for DIISO-HSA are 
      specific but insensitive markers of DA. This study was performed to evaluate test 
      characteristics of the in vitro MCP-1 assay compared with DIISO-HSA-specific 
      immunoglobulin (Ig) G and IgE in identifying workers with DA. MCP-1 was 
      quantitated in peripheral blood mononuclear cell supernatants 48 hours after 
      incubation with DIISO-HSA antigens. Assay results were compared with outcomes of 
      specific inhalation challenge (SIC) testing. Nineteen of 54 (35%) workers assayed 
      for antibodies and MCP-1 stimulation had SIC-confirmed DA. Mean MCP-1 produced by 
      SIC-positive workers was greater than SIC-negative workers (p < or = 0.001). 
      Diagnostic sensitivity, specificity, and test efficiency for specific IgG were 
      47%, 74%, and 65%, respectively, and for specific IgE were 21%, 89%, and 65%, 
      respectively. Sensitivity, specificity, and test efficiency of the MCP-1 test 
      were 79%, 91%, and 87%, respectively. This study indicates that the MCP-1 
      stimulation assay has greater sensitivity and specificity than the specific 
      antibody assays in correctly identifying DA.
FAU - Bernstein, David I
AU  - Bernstein DI
AD  - Department of Internal Medicine, Division of Immunology, College of Medicine, 
      University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH 45267-0563, USA. 
      bernstdd@email.uc.edu
FAU - Cartier, Andre
AU  - Cartier A
FAU - Cote, Johanne
AU  - Cote J
FAU - Malo, Jean-Luc
AU  - Malo JL
FAU - Boulet, Louis-Philippe
AU  - Boulet LP
FAU - Wanner, Mark
AU  - Wanner M
FAU - Milot, Joanne
AU  - Milot J
FAU - L'Archeveque, Jocelyne
AU  - L'Archeveque J
FAU - Trudeau, Carole
AU  - Trudeau C
FAU - Lummus, Zana
AU  - Lummus Z
LA  - eng
GR  - R01 OH 03519-01/OH/NIOSH CDC HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Validation Study
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Chemokine CCL2)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Isocyanates)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
CIN - Am J Respir Crit Care Med. 2002 Aug 15;166(4):436-7. PMID: 12186815
MH  - Adult
MH  - Asthma/blood/*chemically induced/*diagnosis/immunology
MH  - Bronchial Provocation Tests/methods/standards
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Immunoassay/*methods/standards
MH  - Immunoglobulin E/blood
MH  - Immunoglobulin G/blood
MH  - Isocyanates/*adverse effects
MH  - Leukocytes, Mononuclear/immunology
MH  - Male
MH  - Occupational Diseases/blood/*chemically induced/*diagnosis/immunology
MH  - Occupational Exposure/*adverse effects
MH  - Sensitivity and Specificity
EDAT- 2002/08/21 10:00
MHDA- 2002/09/07 10:01
CRDT- 2002/08/21 10:00
PHST- 2002/08/21 10:00 [pubmed]
PHST- 2002/09/07 10:01 [medline]
PHST- 2002/08/21 10:00 [entrez]
AID - 10.1164/rccm.2109018 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 2002 Aug 15;166(4):445-50. doi: 10.1164/rccm.2109018.